论文部分内容阅读
目的评价4种不同方案治疗小儿支原体肺炎的药物经济学效果。方法运用药物经济学成本-效果分析法,对阿奇霉素-阿奇霉素序贯疗法组(A组)、(阿奇霉素+氨溴索)-阿奇霉素序贯疗法组(B组)、红霉素-阿奇霉素序贯疗法组(C组)和(红霉素+氨溴索)-阿奇霉素序贯疗法组(D组)4种治疗方案进行回顾性分析评价。结果4组治愈率分别为78.95%、87.80%、82.05%、88.89%(χ2=5.27,P>0.05);成本分别为(1268.6±126.5)、(1185.3±114.2)、(1124.2±105.3)、(1062.4±96.6)元(F=2.78,P<0.05);成本-效果比分别为16.07±1.60、13.50±1.30、13.70±1.28和11.95±1.09(F=3.98,P<0.01)。结论D组为最佳治疗方案。
Objective To evaluate the pharmacological effects of 4 different treatments for children with mycoplasma pneumonia. Methods The cost-effectiveness analysis method was used to evaluate the effect of azithromycin-azithromycin sequential therapy group (group A), azithromycin-ambroxol-azithromycin sequential therapy group (group B), sequential therapy with erythromycin-azithromycin (C group) and (erythromycin + ambroxol) - azithromycin sequential therapy group (D group) four kinds of treatment regimens were retrospectively analyzed and evaluated. Results The cure rates of the four groups were 78.95%, 87.80%, 82.05% and 88.89% respectively (χ2 = 5.27, P> 0.05); the costs were (1268.6 ± 126.5), (1185.3 ± 114.2) and (F = 2.78, P <0.05). The cost-effect ratios were 16.07 ± 1.60, 13.50 ± 1.30, 13.70 ± 1.28 and 11.95 ± 1.09 respectively (F = 3.98, P <0.01). Conclusion D group is the best treatment.